Cytek Biosciences Correlations
CTKB Stock | USD 6.50 0.09 1.40% |
The current 90-days correlation between Cytek Biosciences and Orthopediatrics Corp is 0.33 (i.e., Weak diversification). The correlation of Cytek Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Cytek Biosciences Correlation With Market
Poor diversification
The correlation between Cytek Biosciences and DJI is 0.65 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cytek Biosciences and DJI in the same portfolio, assuming nothing else is changed.
Cytek |
Moving together with Cytek Stock
0.78 | LH | Laboratory | PairCorr |
0.69 | VREX | Varex Imaging Corp | PairCorr |
0.79 | CAH | Cardinal Health | PairCorr |
0.67 | UNH | UnitedHealth Group Fiscal Year End 10th of January 2025 | PairCorr |
0.72 | LNSR | LENSAR Inc | PairCorr |
0.77 | MMSI | Merit Medical Systems | PairCorr |
0.69 | RDNT | RadNet Inc | PairCorr |
0.83 | ATEC | Alphatec Holdings Buyout Trend | PairCorr |
Moving against Cytek Stock
0.73 | TFX | Teleflex Incorporated | PairCorr |
0.61 | GCTK | GlucoTrack | PairCorr |
0.57 | ZJYL | JIN MEDICAL INTERNATIONAL | PairCorr |
0.49 | FEMY | Femasys | PairCorr |
0.48 | AHG | Akso Health Group | PairCorr |
0.45 | XTNT | Xtant Medical Holdings | PairCorr |
0.43 | CNC | Centene Corp Sell-off Trend | PairCorr |
0.38 | ELV | Elevance Health Fiscal Year End 22nd of January 2025 | PairCorr |
0.35 | MASS | 908 Devices | PairCorr |
0.62 | ACET | Adicet Bio Buyout Trend | PairCorr |
0.44 | VALN | Valneva SE ADR | PairCorr |
0.43 | TNDM | Tandem Diabetes Care | PairCorr |
0.42 | NEUE | NeueHealth Symbol Change | PairCorr |
0.37 | MXCT | MaxCyte | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cytek Stock performing well and Cytek Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cytek Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
KIDS | 2.45 | (0.41) | 0.00 | (0.23) | 0.00 | 4.85 | 16.62 | |||
ELMD | 2.50 | 0.99 | 0.36 | 1.07 | 1.92 | 6.65 | 13.47 | |||
LUNG | 3.16 | (0.41) | 0.00 | (0.10) | 0.00 | 8.44 | 20.44 | |||
RXST | 1.73 | (0.42) | 0.00 | (0.23) | 0.00 | 2.19 | 12.89 | |||
AXGN | 2.20 | 0.01 | 0.01 | 0.13 | 3.70 | 4.73 | 21.60 | |||
TMCI | 3.14 | 0.00 | 0.15 | 0.12 | 2.62 | 6.08 | 38.73 | |||
OFIX | 1.84 | 0.02 | 0.03 | 0.14 | 2.07 | 3.90 | 12.11 | |||
NPCE | 3.46 | 0.18 | 0.10 | 0.20 | 3.15 | 9.73 | 35.38 | |||
INGN | 1.95 | (0.54) | 0.00 | (0.32) | 0.00 | 3.57 | 22.50 | |||
SRDX | 0.48 | (0.05) | (0.21) | (0.02) | 0.59 | 1.26 | 3.22 |
Cytek Biosciences Corporate Management
Todd Garland | Chief Officer | Profile | |
Ming Yan | CTO Director | Profile | |
Melik Ulusu | Senior Chain | Profile | |
Mark Edinger | VP Affairs | Profile | |
Allen Poirson | Senior Development | Profile | |
Connie Wedel | Chief Officer | Profile |